- Home
- CRSP vs NSA Comparison
CRSP vs NSA Comparison
Compare CRSP & NSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRSP
- NSA
- Stock Information
- Founded
- CRSP 2013
- NSA 2013
- Country
- CRSP Switzerland
- NSA United States
- Employees
- CRSP N/A
- NSA N/A
- Industry
- CRSP Biotechnology: Biological Products (No Diagnostic Substances)
- NSA Real Estate Investment Trusts
- Sector
- CRSP Health Care
- NSA Real Estate
- Exchange
- CRSP Nasdaq
- NSA Nasdaq
- Market Cap
- CRSP 3.3B
- NSA 2.8B
- IPO Year
- CRSP 2016
- NSA 2015
- Fundamental
- Price
- CRSP $44.25
- NSA $32.39
- Analyst Decision
- CRSP Buy
- NSA Hold
- Analyst Count
- CRSP 15
- NSA 10
- Target Price
- CRSP $70.62
- NSA $40.83
- AVG Volume (30 Days)
- CRSP 2.5M
- NSA 1.1M
- Earning Date
- CRSP 08-04-2025
- NSA 08-04-2025
- Dividend Yield
- CRSP N/A
- NSA 7.05%
- EPS Growth
- CRSP N/A
- NSA N/A
- EPS
- CRSP N/A
- NSA 0.12
- Revenue
- CRSP $37,675,000.00
- NSA $742,357,000.00
- Revenue This Year
- CRSP $30.25
- NSA N/A
- Revenue Next Year
- CRSP $268.62
- NSA $3.62
- P/E Ratio
- CRSP N/A
- NSA $267.07
- Revenue Growth
- CRSP N/A
- NSA N/A
- 52 Week Low
- CRSP $30.04
- NSA $30.88
- 52 Week High
- CRSP $63.68
- NSA $49.44
- Technical
- Relative Strength Index (RSI)
- CRSP 68.22
- NSA 33.88
- Support Level
- CRSP $42.17
- NSA $32.70
- Resistance Level
- CRSP $47.04
- NSA $33.43
- Average True Range (ATR)
- CRSP 2.30
- NSA 0.67
- MACD
- CRSP 0.47
- NSA -0.06
- Stochastic Oscillator
- CRSP 74.56
- NSA 12.06
About CRSP CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
About NSA National Storage Affiliates Trust of Beneficial Interest
National Storage Affiliates Trust Trust is a real estate investment trust. The company owns, operates, and acquires self-storage properties located within the metropolitan statistical areas throughout the United States. With the help of property management platform, the company manages and controls the day-to-day operations and affairs of consolidated properties and unconsolidated real estate ventures under the iStorage, SecurCare, RightSpace, Northwest and Move It brands.